The objective of this proposal is to investigate the preventive role of soy isoflavones in prostate cancer (PCA) progression and angiogenesis.
The specific aims are: l) to study the effects of soy isoflavones on inhibiting expression of membrane-type metalloproteinase (MT-MMP) by PCA cells, fibroblasts, or endothelial cells (ECs) in vitro, and 2) to determine if diets containing soy protein isolate (SPI) or purified isoflavones inhibit prostate tumor progression, angiogenesis, and MT-MMP expression in vivo. Human PCA cells (PC-3, DU 145, and LNCAP), fibroblasts, and ECs will be treated with isoflavones. MMPs-containing conditioned media and MT-MMP-containing plasma membranes will be prepared. RNase protection assays, Western blotting, and zymography will be applied to determine mRNA, protein, and activity of MT-MMP to test the hypothesis that isoflavones inhibit PCA progression, and prostate tumor angiogenesis by inhibiting MT-MMP expression by PCA and fibroblasts, and ECs, respectively. In animal study, human PCA cell-inoculated nude mice will be fed control, SPI-based, or isoflavone-supplemented diets. Tumor sizes will be measured, and tumors removed for determinations of MT-MMP mRNA, protein and activity to evaluate the effects of isoflavones on in vivo inhibition of PCA progression. Anti-angiogenic effect of isoflavones will be evaluated by immunohistochemical analysis of microvessels.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
7F32CA071161-02
Application #
2429915
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1997-05-15
Project End
Budget Start
1997-05-15
Budget End
1998-05-14
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215